CNTX CONTEXT THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CONTEXT THERAPEUTICS INC reported revenue of n/a, net income of −$14.6M and diluted EPS of −$0.15; for the fiscal year ended December 2025 revenue was n/a.
CNTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$39.7M, net income −$36.1M (margin n/a), EPS −$0.38
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$29.9M, net income −$26.7M (margin n/a), EPS −$0.46
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$25.1M, net income −$24.0M (margin n/a), EPS −$1.50
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$15.4M, net income −$14.8M (margin n/a), EPS −$0.93
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$10.5M, net income −$10.5M (margin n/a), EPS −$3.69
CNTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$14.6M, EPS −$0.15
- Quarter ended Mar 31, 2026: revenue n/a, net income −$8.68M, EPS −$0.09
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$13.0M, EPS −$0.14
- Quarter ended Sep 30, 2025: revenue n/a, net income −$9.69M, EPS −$0.10
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.83M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.58M, EPS −$0.05
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.34M, EPS $0.03
- Quarter ended Sep 30, 2024: revenue n/a, net income −$17.5M, EPS −$0.22
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.25M, EPS −$0.04
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.67M, EPS −$0.23
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$6.77M, EPS −$0.42
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.87M, EPS −$0.37
- Quarter ended Jun 30, 2023: revenue n/a, net income −$5.01M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.31M, EPS −$0.40
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.56M, EPS −$0.22
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.85M, EPS −$0.24
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.99M, EPS −$0.25
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.44M, EPS −$0.22
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.09M, EPS $17.04
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.44M, EPS −$4.00
CNTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$26.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$14.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$21.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$13.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$8.80M, share buybacks n/a
CNTX balance sheet
- Jun 30, 2026: cash $43.0M, total assets $46.1M, total liabilities $7.96M, shareholders' equity $38.2M
- Mar 31, 2026: cash $54.5M, total assets $58.9M, total liabilities $6.66M, shareholders' equity $52.2M
- Dec 31, 2025: cash $66.0M, total assets $68.5M, total liabilities $8.02M, shareholders' equity $60.5M
- Sep 30, 2025: cash $76.9M, total assets $79.2M, total liabilities $6.06M, shareholders' equity $73.2M
- Jun 30, 2025: cash $83.5M, total assets $87.2M, total liabilities $4.61M, shareholders' equity $82.5M
- Mar 31, 2025: cash $89.4M, total assets $93.0M, total liabilities $1.98M, shareholders' equity $91.0M
- Dec 31, 2024: cash $94.4M, total assets $98.1M, total liabilities $2.86M, shareholders' equity $95.3M
- Sep 30, 2024: cash $84.8M, total assets $86.3M, total liabilities $2.47M, shareholders' equity $83.9M
Is CNTX profitable?
No. CONTEXT THERAPEUTICS INC lost $46.0M over the last four quarters.
What is CNTX's EPS?
Diluted earnings per share over the last four quarters were −$0.48; −$0.15 in the latest quarter.